Exploring metabolic vulnerability and therapeutic potential in cancers with isocitrate dehydrogenase mutations
<p>Treatment of mutant isocitrate dehydrogenase 1 (IDH1) glioma remains challenging; targeted allosteric inhibitors currently provide limited clinical effect. Resistance to mutIDH1 inhibitors has also emerged in other cancers with mutant <em>IDH1</em>. IDH1 catalyses the decarboxyl...
Tác giả chính: | |
---|---|
Tác giả khác: | |
Định dạng: | Luận văn |
Ngôn ngữ: | Englihs |
Được phát hành: |
2022
|
Những chủ đề: |